A compressed treatment schedule can matter to someone arranging time away from work or traveling internationally. But a faster timetable and a better clinical result are different promises. Two stimulation trials published in 2026 illustrate why families should ask which protocol was tested, against what alternative, and for how long before choosing an accelerated or personalized treatment.
Key findings
104 adults: participants randomized in the March 2026 H1-coil trial; 89 completed its six-week study.
19.02 versus 19.79 points: mean depression-score reductions with the accelerated and standard protocols.
2.73 points: the upper limit of the one-sided 97.5% confidence interval, below the three-point noninferiority margin. That supported the trial’s specified conclusion, not general superiority. [1]
51 patients: randomized in a separate personalized stimulation trial published in September 2026. It did not establish an active-versus-sham advantage on its primary endpoint. [2]
Similar score changes, different schedules
Visual similarity alone does not establish equivalence. The confidence interval and prespecified margin support the study’s noninferiority finding. Source: Hanlon and colleagues, March 3, 2026. [1]
The study reported time to remission of 21 versus 28 days. It also reported more discomfort and headaches in the accelerated group. Several authors disclosed manufacturer-related interests.
A scheduling advantage can be meaningful without making the approach best for every patient. The result concerns the particular device, population, and treatment plan studied.
The second trial asked a different question
The trial published online September 16, 2026 compared two personalized accelerated theta-burst approaches with sham stimulation in treatment-resistant depression. Forty-three of its 51 randomized patients completed the protocol. [2]
The primary one-week MADRS result and secondary anhedonia result showed no statistically significant active-versus-sham differences in either the intention-to-treat or per-protocol analysis. Response and remission also did not differ between arms.
This is not a direct refutation of the March trial. Devices, protocols, participants, and comparators differed. It shows why accelerated TMS should not be treated as one interchangeable intervention.
| Feature | March H1-coil trial | September personalized trial |
|---|---|---|
| Randomized sample | 104 | 51 |
| Comparator | An active standard schedule | Sham stimulation |
| Primary assessment | HDRS-21 change at six weeks | MADRS change at one week |
| Main finding | Noninferiority criterion met | No significant active-versus-sham advantage |
| Does not establish | Universal superiority | That all stimulation approaches are ineffective |
The September online release belongs in Q3 reporting even though the journal issue is dated December. Publication date and issue date are different.
Noninferiority is not just a nonsignificant difference
A noninferiority trial defines how much worse a new approach could be before it would no longer be considered acceptably close to the comparator. Its analysis tests the uncertainty against that margin.
Merely finding no statistically significant difference is not enough. A small study can fail to distinguish treatments while leaving substantial differences plausible.
The margin matters to patients because a practical advantage may involve a clinical trade-off. The discussion should explain both rather than translate noninferior into identical or better.
Personalized is a method, not an outcome
A procedure can use individual information without demonstrating that the resulting decisions improve care. A sophisticated scan or tailored schedule still needs evaluation against an appropriate alternative.
The September trial tested that question for specified approaches. Improvement within an active group alone would not answer it, because other care, expectations, and symptom fluctuation can also contribute.
Its inconclusive advantage does not prove the true effect is exactly zero. It means the study did not establish the claimed difference under its design. Further evidence should address that uncertainty rather than substitute a stronger adjective.
A time-poor patient needs the whole timetable
Assessment, treatment days, time at the clinic, travel, review, and continuing care all affect the practical burden. A compressed initial schedule is not automatically the end of treatment.
In the March protocol, concentrated initial treatment was followed by additional sessions. Its primary comparison remained at six weeks. Presenting it simply as treatment finished in a few days would lose that context. [1]
A convenient local service may require repeated visits. A concentrated intervention abroad may need local continuation. The useful choice is a clinically suitable pathway the person can realistically complete.
Clinical needs should lead the technology choice
A person who has tried several treatments may reasonably want a more effective next step. The decision still requires a clear history of what was tried, how it was delivered, what changed, and why it ended.
A technically advanced option is not automatically the next treatment for everyone. Nor does a disappointing result with one approach prove that every alternative will fail.
Ask how closely the supporting trial matches the proposed device, target, schedule, and patient population. A provider using a different protocol should explain its evidence rather than borrow the most favorable finding in the field.
Discomfort and later follow-up belong in the decision
The March trial’s greater discomfort and headaches matter alongside its speed findings. A concentrated schedule may be acceptable to one person and difficult for another.
Six-week symptom improvement does not establish a year of recovery. Longer follow-up should report functioning, recurrence, additional treatment, and who could not be assessed.
The person should know when progress is reviewed and what happens if treatment is interrupted. A fixed package should not replace reassessment when clinical circumstances change.
Questions before paying for a compressed program
| Question | Useful information |
|---|---|
| Is this the studied protocol? | Device, target, schedule, support, and eligibility |
| What was the comparator? | Sham, active treatment, or another design |
| What did improvement mean? | Measure, threshold, denominator, and timing |
| What is the total commitment? | Initial sessions, reviews, and continuing care |
| What happens if the plan changes? | Clinical review and practical alternatives |
| How were results evaluated? | Missing data, assessment methods, and financial disclosures |
The framework is not a device recommendation or a clinic ranking. THE BALANCE should answer the same questions when describing a treatment’s evidence.
International access needs its own check
A trial publication does not establish current authorization for every protocol in every country. A family considering care across borders should obtain a current assessment of the relevant clinical and regulatory requirements.
It should also confirm who reviews progress after returning home. A portable report is not the same as an accepted receiving relationship.
These are practical client-group considerations, not findings that wealthy or internationally mobile patients respond differently. Neither trial established an HNW-specific treatment effect or a change in business performance.
What stronger future evidence should add
Replication in relevant settings would help determine how broadly each result applies. Longer-term comparisons should examine meaningful functioning as well as symptom scores.
A complete burden-of-care evaluation would count the whole pathway rather than only calendar days in the initial phase. It should include adverse effects, interruptions, and subsequent care.
Funding disclosures should remain visible, but do not determine whether a result is true on their own. Methods, outcomes, and independent scrutiny still need examination.
The bottom line
Make the claim as specific as the evidence. A faster schedule may be worthwhile, and personalization may be a valuable research direction. Neither should bypass the question of which protocol helps which patients, against which alternative, and over what period.
For journalists
Key contrast: one 2026 trial supported noninferiority to an active schedule; another did not establish an advantage over sham.
Important caveat: the studies tested different interventions and do not support a blanket conclusion about all TMS.
Suggested attribution: THE BALANCE comparison of two published 2026 stimulation trials.
Methodology and sources
This narrative comparison preserves the separate clinical questions and endpoints. The chart shows reported mean reduction magnitudes, not remission percentages or invented uncertainty. Results were not pooled.
- Hanlon and colleagues. Accelerated TMS with the H1-coil for depression: multisite randomized noninferiority trial. March 3, 2026. DOI 10.1016/j.brs.2026.103050.
- Appelbaum and colleagues. Connectivity- and frequency-individualized accelerated intermittent theta burst stimulation. September 16, 2026. DOI 10.1016/j.jad.2026.122515.
